New indications discovery, repurposing, repositioning, rescue
- Target validation
- Liability Assessment
- New indications discovery
Phenotypic characterization of genetically-modified animals plays a critical role in the drug target validation process. Researcher needs vary, depending on the stage and specific goals of a drug discovery and development program. Invivotek scientists are experts and will custom-design each phenotyping project to best meet the project goals and to provide interpretive data analysis.
We offer an in-depth disease–oriented phenotyping assessment with an emphasis on autoimmune and inflammatory disorders, metabolism, diabetes and obesity. By multiplexing bioassays spanning multiple therapeutic areas, we provide a powerful tool for assessment of potential on-target side effects and early identification of new therapeutic indications for genetic targets. Sequential evaluation of animals in smart-designed and multiplexed validated bioassay combinations maximizes the quality data set per animal, delivering significant savings in time, cost and animal resources.
Invivotek has experience with almost 100 standardized and validated bioassays to support pre-clinical research related to treatments in the following:
- Autoimmune Diseases
- Metabolic and Cardiovascular Diseases
- Pain and CNS
Your Success Is Our Priority
Maintaining high quality standards while meeting deadlines is as important to Invivotek as it is to you. We work with our clients to define all of the critical steps for project optimization and success:
- Define project scope
- Set project goals, create timelines and establish milestones
- Issue status reports for each milestone
- Provide a final study report, which includes complete statistical analysis and data interpretation at project completion